Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

Exclusion Criteria

• •1. Administration of lipid lowering agents for more than one week within 4 weeks prior to screening visit
• •2. Uncontrollable diabetes with HbA1c ≥ 8.5%
• •3. Fasting LDL-C ≤ 70 mg/dL
• •4. Fasting triglyceride ≥ 400 mg/dL
• •5. Total cholesterol ≥ 300 mg/dL
• •6. History of muscular disease or rhabdomyolysis due to use of statin
• •7. Hypersensitive to rosuvastatin or ezetemibe
• •8. Contraindications stated in the SPC of rosuvastatin or rosuvastatin/ezetimibe including the following:
• •① Severe renal disease (estimated GFR(MDRD) \< 30mL/min/1.73m2)
• •② ALT, AST \> 3x ULN or history of active liver disease
• •③ CPK \> 3x ULN
• •9. Administration of other investigational products within 30 days prior to screening visit
• •10. Other than the above who is deemed to be ineligible to participate in the trial by investigator